WASHINGTON (Reuters) -The U.S. Supreme Court on Monday declined to hear a bid by Sanofi SA to revive its antitrust lawsuit accusing rival pharmaceutical company Viatris Inc of illegally monopolizing ...

The U.S. Supreme Court on Monday declined to hear a case filed by Sanofi (NASDAQ:SNY) to revive an antitrust lawsuit that charged Viatris (NASDAQ:VTRS) of illegally monopolizing the U.S. market for ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. ADRENALINE VIATRIS contains the active ingredient adrenaline ...

Sanofi claimed Viatris (formerly Mylan) used rebates to pharmacy benefit managers to secure monopoly A 10th Circuit panel said negotiating exclusivity for lower consumer prices was legal (Reuters) - ...

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Viatris Inc. is one of them. Viatris Inc. (NASDAQ:VTRS), formed from the 2020 merger of Mylan ...

Viatris Inc (NASDAQ:VTRS) saw its stock increase by 2.6% after the U.S. Food and Drug Administration approved its Iron Sucrose Injection, USP, marking the first generic alternative to Venofer® ...

Approval Granted with Competitive Generic Therapy Eligibility for 100mg/5mL and 200mg/10mL Strengths; Provides Eligibility for 180 Days of Exclusivity Viatris Chief R&D Officer Philippe Martin said, ...

WASHINGTON, April 17 (Reuters) - The U.S. Supreme Court on Monday declined to hear a bid by Sanofi SA (SASY.PA), opens new tab to revive its antitrust lawsuit accusing rival pharmaceutical company ...